From the publisher of this report:
In this report, we analyze the perspectives of more than 350 providers in the therapeutic areas with the most potential for disruption in the year ahead:rheumatology, gastroenterology, dermatology and ophthalmology. Combined with perspectives from leading experts, we give a view of the industry and the imminent market shift that will come from competition with Humira™ and biosimilar utilization. We also analyze the latest industry data on utilization, government pricing reform, and payer coverage.
View Report